Andrew C. Orth serves as Executive at Krystal Biotech, Inc., where they oversee executive responsibilities. Since joining the company, Andrew C. Orth has executed 4 insider transactions totaling $1.6M, demonstrating a bearish approach to their equity position. Their most recent transaction on Jun 9, 2023 involved selling 5,261 shares valued at $673.9K.
Andrew C. Orth currently holds 7,339 shares of Krystal Biotech, Inc. (KRYS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Andrew C. Orth has been a net seller of KRYS stock. They have purchased $0 and sold $1.6M worth of shares.
Andrew C. Orth's most recent insider trade was on Jun 9, 2023, when they sold 5,261 shares at $128.10 per share.
Get notified when new Form 4 filings are submitted
| $129.70 |
| Planned |
| Jun 9, 2023 | KRYS | $890.5K | Sale | 6,906 | $128.94 | Planned |
| Jun 9, 2023 | KRYS | $794.4K | Option Exercise | 12,500 | $63.55 | Planned |